The oncology drug market continues to grow, with innovative cancer treatment paradigms such as YB1 oncolytic bacteria offering new hope.

Today, cancer is still one of the leading causes of death worldwide each year, and a wide range of malignant tumours continue to pose a severe threat to human life and health, with tens of millions of cancer patients waiting for more ways to deal with the disease and to fight it.

The number of cancer cases worldwide has been increasing over the years. It is expected to continue to grow due to factors such as increasing life expectancy and an ageing population. This high incidence of cancer has created a sizeable clinical demand for oncology drugs globally, thus driving the continued growth of the global oncology drugs market.

Because of the vast unmet demand that exists and is expected to expand further in the future, the global oncology drug market also has tremendous scope for growth and expansion. In recent years, it has become a "strategic location" for global pharmaceutical companies to enter.

According to industry research reports, the global oncology drugs market will expand from US$93.7 billion to US$150.3 billion from 2016 to 2020, accounting for 8.1% and 11.6% of the global pharmaceutical market, respectively, at a CAGR of 12.5% during this period. This steadily growing market is driven by a combination of an expanding patient population, increasing affordability of healthcare services, and the emergence of innovative and advanced therapies.

The global oncology market is expected to reach US$304.8 billion by 2025. It accounts for 17.8% of the global pharmaceutical market. Furthermore, it grows at a CAGR of 15.2% during the forecast period from 2020 to 2025. the global oncology market is expected to generate US$482.5 billion in revenue by 2030, growing at a CAGR of 9.6% from 2025 to 2030.

The Attacking US Oncology Drug Market & China Oncology Drug Market

The US and China are the most representative regional "leaders", respectively, looking at the global oncology drug market. The development trends of the two markets almost dominate the overall pattern of the future development of the global oncology drug market.

The US oncology drugs market size reaches USD 101.4 billion in 2020, growing at a CAGR of 17% from 2015 to 2020. The US oncology drugs market is expected to increase to reach US$214.3 billion in 2030, driven by the market launch of more speciality oncology drugs.

The market for oncology drugs in China will reach US$31.9 billion in 2020, growing at a CAGR of 14.8% from 2015 to 2020. Due to the relatively late introduction of molecularly targeted drugs and biologics in China, many cancer patients cannot be adequately treated with conventional chemotherapy drugs, leading to a growing demand for new and excellent treatments.

Nevertheless, this unmet need is being addressed through increased affordability and supportive policies for new drug development and approval, which is expected to drive accelerated growth in the Chinese oncology drugs market. As a result, the Chinese oncology drugs market is expected to experience rapid growth in the coming years, reaching US$80.6 billion by 2030.

Overall, the continued growth of the oncology market in China and the United States is being driven by several factors.

Firstly, the introduction of innovative drugs and combination therapies: continued and significant investment in research and development is facilitating the development of new treatments, such as innovative RNAi therapies, cellular therapies, gene therapies and oncolytic viral and oncolytic bacterial therapies, which are expected to bring better efficacy and safety for new indications. In addition, the development of combination therapies is expected to expand access to treatment for unapproved indications.

Secondly, the expanded use and long-term maintenance of oncology drugs: Currently, drugs are gradually being developed to cover different stages of cancer treatment, including neoadjuvant and adjuvant therapy. In addition, formulations with excellent safety and convenience allow long-term maintenance for oncology patients.

Thirdly, the increasing incidence of cancer leads to growing clinical demand: the ageing trend is expected to continue in the coming decades. Furthermore, with cancer and its associated sequelae having a more significant impact on older people, the ageing population will lead to a continued increase in cancer incidence in the population.

Innovative cancer treatment brings the light of hope to patients worldwide.

We already know that cancer treatment has evolved over a long time throughout history and believe that the mainstream cancer treatment paradigm will continue to innovate, iterate, and grow over time as scientists worldwide innovate and work.

Currently, the primary cancer treatments include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. Conventional treatments such as radiotherapy and chemotherapy have been widely used in the past, but they inevitably have side effects and limited efficacy.

Targeted treatments, which have lately become the central therapeutic paradigm, target particular molecules such as proteins or enzymes in cellular processes involved in cancer formation or genetic mutations that play a role in cancer dissemination. Immunotherapy, which has also become the dominant treatment modality, uses the patient's immune system to fight cancer.

That can be said that targeted therapies and immunotherapies have revolutionised cancer treatment and are now replacing traditional therapies as the next generation of pillar cancer treatments. Currently, most targeted therapies are small-molecule drugs or monoclonal antibodies, while immunotherapies include cytokines, monoclonal antibodies, checkpoint inhibitors, peripatetic T-cell therapies and cancer vaccines.

To date, these new forms of oncology drugs have shown great potential and have brought a ray of hope to millions of cancer patients worldwide.

Of course, the commercialisation of innovative oncology drugs will need to be facilitated by several factors, and its success will depend on a wide range of factors, including a large amount of reliable clinical data, recommendations from key opinion leaders in the pharmaceutical field, treatment guidance, health insurance coverage of drugs and local pricing strategies.

Therefore, a friendly policy and market development environment is an indispensable and vital ground for innovative oncology drug research and development. In terms of the current situation of China's novel oncology drug research and development industry, the market pattern of innovative oncology drugs in China is developing rapidly in a positive and healthy direction. The national regulatory authorities also encourage innovative medicines' research, development, and marketing.

The Chinese government has emphasised encouraging innovation in the healthcare industry in recent years. The momentum of innovation in the industry has not stopped since last year in the face of the difficulties caused by the new crown epidemic, with innovation becoming the new normal in the Chinese pharmaceutical market. Driven by favourable government policy support and market factors such as emerging cell and gene therapies, companies in the industry are increasingly focusing on developing innovative drugs and are actively expanding their R&D capabilities and product lines.

HKND with YB1 actively competes in the new drug creation circuit.

In an industry climate of active innovation and increased investment in research and development, several new innovative biotechnology companies have emerged. As the world's first salmonella drug delivery bacterial vector YB1, HKND has also attracted widespread attention from the industry with its groundbreaking and innovative technological research results.

We are a scientific and innovative research and development company specialising in biomolecular drug delivery systems. Our core technology, YB1, can deliver a wide range of biomolecular drugs with high efficiency. Our research has demonstrated that YB1 can provide a wide range of large molecule anti-cancer drugs, such as protein drugs, mRNA vaccines. Antibodies, oncolytic viruses, etc., carry a wide range of thrombolytic drugs to treat various types of thrombotic diseases.

From the results of experimental studies, YB1 has strong technical compatibility, enabling compatibility with chemical drugs, immune checkpoint antibodies and cellular technologies such as CAR-T, increasing efficacy and diversifying product pipeline design.

The company has several pipelines of products in development for YB1 applications, including seven YB1 oncolytic bacterial pipelines for sarcoma. Melanoma, other solid tumours, and three YB1 thrombolytic bacterial channels for YB1-carrying recombinant urokinase (rt-PA). YB1-carrying recombinant fibrinolytic enzymes and YB1-carrying fibrinolytic enzymes for various thrombotic diseases.

As the YB1 technology matures and more innovative biotech companies in the industry move into broader markets, the global biotech and healthcare sector is poised for a new era. We look forward to a new round of industry explosion.